PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 5717人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1255035, encodeId=ab7212550358d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Blood：EBV-miR-BHRF1-2-5p微调控PD-L1/PD-L2的扩增, objectType=article, longId=182603, objectId=9dcb1826033e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9dcb1826033e, replyNumber=0, likeNumber=50, createdTime=2019-11-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9dcb1826033e, moduleTitle=Blood：EBV-miR-BHRF1-2-5p微调控PD-L1/PD-L2的扩增, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9dcb1826033e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255034, encodeId=cd3412550341a, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=当PD-1 / PD-L1抑制剂耐药时，MRx0518联合KEYTRUDA是一种潜在治疗手段, objectType=article, longId=182558, objectId=c766182558a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c766182558a7, replyNumber=0, likeNumber=103, createdTime=2019-11-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c766182558a7, moduleTitle=当PD-1 / PD-L1抑制剂耐药时，MRx0518联合KEYTRUDA是一种潜在治疗手段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c766182558a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255033, encodeId=a4121255033dc, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=股票大涨248%！热烈祝贺陈列平教授！祝贺NextCure！SIGLEC15有望媲美PD-1、PD-L1！, objectType=article, longId=182509, objectId=56161825092c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56161825092c, replyNumber=0, likeNumber=47, createdTime=2019-11-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56161825092c, moduleTitle=股票大涨248%！热烈祝贺陈列平教授！祝贺NextCure！SIGLEC15有望媲美PD-1、PD-L1！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56161825092c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255032, encodeId=31b312550329f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, objectType=article, longId=181787, objectId=0d52181e8763, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d52181e8763, replyNumber=0, likeNumber=14, createdTime=2019-10-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d52181e8763, moduleTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d52181e8763)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255031, encodeId=d72a125503159, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Scand J Immunol：过敏性鼻炎患者中PD-1/PD-L1途径的阻断能够促进CD19+ CD25+ Bregs细胞凋亡和抑制IL-10的分泌, objectType=article, longId=181815, objectId=99801818158b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99801818158b, replyNumber=0, likeNumber=65, createdTime=2019-10-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99801818158b, moduleTitle=Scand J Immunol：过敏性鼻炎患者中PD-1/PD-L1途径的阻断能够促进CD19+ CD25+ Bregs细胞凋亡和抑制IL-10的分泌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99801818158b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255030, encodeId=f4f6125503062, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=K药治疗中国食管癌生存率翻倍无论PD-L1表达 ——解读KEYNOTE-181中国亚组分析结果, objectType=article, longId=180885, objectId=c2e718088544, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2e718088544, replyNumber=0, likeNumber=72, createdTime=2019-10-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2e718088544, moduleTitle=K药治疗中国食管癌生存率翻倍无论PD-L1表达 ——解读KEYNOTE-181中国亚组分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2e718088544)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255029, encodeId=5ebb125502904, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效, objectType=article, longId=180569, objectId=13a6180569e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13a6180569e0, replyNumber=0, likeNumber=72, createdTime=2019-10-07, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13a6180569e0, moduleTitle=2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13a6180569e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255028, encodeId=c3a61255028d5, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期, objectType=article, longId=180568, objectId=34561805686b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34561805686b, replyNumber=0, likeNumber=56, createdTime=2019-10-07, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34561805686b, moduleTitle=2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34561805686b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255027, encodeId=297c125502e88, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=英国NICE对罗氏的PD-L1单抗Tecentriq治疗晚期乳腺癌say, objectType=article, longId=180564, objectId=58f6180564c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58f6180564c6, replyNumber=0, likeNumber=63, createdTime=2019-10-07, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58f6180564c6, moduleTitle=英国NICE对罗氏的PD-L1单抗Tecentriq治疗晚期乳腺癌say, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58f6180564c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255026, encodeId=241b1255026ea, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=纳武利尤单抗食管癌首秀：无论PD-L1表达，患者总生存期获益均显著优于化疗, objectType=article, longId=180503, objectId=941618050315, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=941618050315, replyNumber=0, likeNumber=67, createdTime=2019-10-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=941618050315, moduleTitle=纳武利尤单抗食管癌首秀：无论PD-L1表达，患者总生存期获益均显著优于化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=941618050315)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255025, encodeId=8cdb1255025d7, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, objectType=article, longId=180179, objectId=775a1801e9d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=775a1801e9d4, replyNumber=0, likeNumber=83, createdTime=2019-09-29, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=775a1801e9d4, moduleTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=775a1801e9d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255024, encodeId=f5981255024be, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=国内PD-1/PD-L1抑制剂亟需冷静, objectType=article, longId=179967, objectId=0ce11e9967da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ce11e9967da, replyNumber=0, likeNumber=63, createdTime=2019-09-26, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ce11e9967da, moduleTitle=国内PD-1/PD-L1抑制剂亟需冷静, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ce11e9967da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255023, encodeId=58ad125502387, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=张会来教授：PD-1/PD-L1单克隆抗体在恶性淋巴瘤的研究方向与热点问题, objectType=article, longId=179922, objectId=9aec1e992277, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aec1e992277, replyNumber=0, likeNumber=49, createdTime=2019-09-25, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aec1e992277, moduleTitle=张会来教授：PD-1/PD-L1单克隆抗体在恶性淋巴瘤的研究方向与热点问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aec1e992277)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255022, encodeId=0b6212550226b, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=2019 CSCO：抗PD-L1抗体CS1001治疗MSI-H实体瘤有效性好、安全性高, objectType=article, longId=179912, objectId=89001e991243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89001e991243, replyNumber=0, likeNumber=95, createdTime=2019-09-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89001e991243, moduleTitle=2019 CSCO：抗PD-L1抗体CS1001治疗MSI-H实体瘤有效性好、安全性高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89001e991243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255021, encodeId=91ea125502164, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Gastroenterology：PD-L1表达在原发性胃和肠弥漫性大B细胞淋巴瘤中的预后影响, objectType=article, longId=179701, objectId=85981e970172, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85981e970172, replyNumber=0, likeNumber=49, createdTime=2019-09-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85981e970172, moduleTitle=J Gastroenterology：PD-L1表达在原发性胃和肠弥漫性大B细胞淋巴瘤中的预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85981e970172)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255020, encodeId=8b4a125502069, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=中国首部PD-1/PD-L1单抗使用后导致的肺炎诊疗共识重磅发布！ | 2019 CTS, objectType=article, longId=179124, objectId=69531e9124ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69531e9124ad, replyNumber=0, likeNumber=74, createdTime=2019-09-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69531e9124ad, moduleTitle=中国首部PD-1/PD-L1单抗使用后导致的肺炎诊疗共识重磅发布！ | 2019 CTS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69531e9124ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255019, encodeId=d2a31255019e8, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌, objectType=article, longId=178551, objectId=036a1e8551e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=036a1e8551e1, replyNumber=0, likeNumber=51, createdTime=2019-09-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=036a1e8551e1, moduleTitle=欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=036a1e8551e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255018, encodeId=27581255018bc, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=加拿大卫生部批准罗氏PD-L1单抗Tecentriq治疗小细胞肺癌，这是20年来加拿大批准治疗该疾病的新疗法, objectType=article, longId=177619, objectId=7d301e761945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d301e761945, replyNumber=0, likeNumber=73, createdTime=2019-08-16, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d301e761945, moduleTitle=加拿大卫生部批准罗氏PD-L1单抗Tecentriq治疗小细胞肺癌，这是20年来加拿大批准治疗该疾病的新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d301e761945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255017, encodeId=929d125501e18, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=继PD1/PD-L1之后，谁能成为下一个肿瘤逃逸的经典通路？, objectType=article, longId=177496, objectId=d1b61e749623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1b61e749623, replyNumber=0, likeNumber=72, createdTime=2019-08-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1b61e749623, moduleTitle=继PD1/PD-L1之后，谁能成为下一个肿瘤逃逸的经典通路？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1b61e749623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255016, encodeId=dd5e125501624, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：PD-L1用于新诊断的晚期经典霍奇金淋巴瘤, objectType=article, longId=177428, objectId=30a21e7428a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30a21e7428a5, replyNumber=0, likeNumber=87, createdTime=2019-08-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30a21e7428a5, moduleTitle=JCO：PD-L1用于新诊断的晚期经典霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30a21e7428a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Blood：EBV-miR-BHRF1-2-5p微调控PD-L1/PD-L2的扩增

2019-11-09

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

当PD-1 / PD-L1抑制剂耐药时，MRx0518联合KEYTRUDA是一种潜在治疗手段

2019-11-09

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

股票大涨248%！热烈祝贺陈列平教授！祝贺NextCure！SIGLEC15有望媲美PD-1、PD-L1！

2019-11-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功

2019-10-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Scand J Immunol：过敏性鼻炎患者中PD-1/PD-L1途径的阻断能够促进CD19+ CD25+ Bregs细胞凋亡和抑制IL-10的分泌

2019-10-23

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

K药治疗中国食管癌生存率翻倍无论PD-L1表达 ——解读KEYNOTE-181中国亚组分析结果

2019-10-12

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效

2019-10-07

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期

2019-10-07

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

英国NICE对罗氏的PD-L1单抗Tecentriq治疗晚期乳腺癌say

2019-10-07

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

纳武利尤单抗食管癌首秀：无论PD-L1表达，患者总生存期获益均显著优于化疗

2019-10-06

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果

2019-09-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

国内PD-1/PD-L1抑制剂亟需冷静

2019-09-26

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

张会来教授：PD-1/PD-L1单克隆抗体在恶性淋巴瘤的研究方向与热点问题

2019-09-25

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

2019 CSCO：抗PD-L1抗体CS1001治疗MSI-H实体瘤有效性好、安全性高

2019-09-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Gastroenterology：PD-L1表达在原发性胃和肠弥漫性大B细胞淋巴瘤中的预后影响

2019-09-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

中国首部PD-1/PD-L1单抗使用后导致的肺炎诊疗共识重磅发布！ | 2019 CTS

2019-09-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌

2019-09-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

加拿大卫生部批准罗氏PD-L1单抗Tecentriq治疗小细胞肺癌，这是20年来加拿大批准治疗该疾病的新疗法

2019-08-16

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

继PD1/PD-L1之后，谁能成为下一个肿瘤逃逸的经典通路？

2019-08-14

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：PD-L1用于新诊断的晚期经典霍奇金淋巴瘤

2019-08-12

科室
- - 订阅+
  - 更多科室
工具
服务